Entecavir Mylan

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
16-01-2024
Valmisteyhteenveto Valmisteyhteenveto (SPC)
16-01-2024

Aktiivinen ainesosa:

entecavir monohydrate

Saatavilla:

Mylan Pharmaceuticals Limited

ATC-koodi:

J05AF10

INN (Kansainvälinen yleisnimi):

entecavir

Terapeuttinen ryhmä:

Antivirals for systemic use

Terapeuttinen alue:

Hepatitis B

Käyttöaiheet:

Entecavir Mylan is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.decompensated liver disease.For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.Entecavir Mylan is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to

Tuoteyhteenveto:

Revision: 6

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2017-09-18

Pakkausseloste

                                44
B. PACKAGE LEAFLET
45
PACKAGE LEAFLET: INFORMATION FOR THE USER
ENTECAVIR VIATRIS 0.5 MG FILM-COATED TABLETS
ENTECAVIR VIATRIS 1 MG FILM-COATED TABLETS
entecavir
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Entecavir Viatris is and what it is used for
2.
What you need to know before you take Entecavir Viatris
3.
How to take Entecavir Viatris
4.
Possible side effects
5.
How to store Entecavir Viatris
6.
Contents of the pack and other information
1.
WHAT ENTECAVIR VIATRIS IS AND WHAT IT IS USED FOR
ENTECAVIR VIATRIS TABLETS ARE ANTI-VIRAL MEDICINES, USED TO TREAT
CHRONIC (LONG TERM) HEPATITIS B
VIRUS (HBV) INFECTION IN ADULTS.
Entecavir Viatris can be used in people whose liver is damaged but
still functions properly (compensated liver disease) and in people
whose liver is damaged and does not
function properly (decompensated liver disease).
ENTECAVIR VIATRIS TABLETS ARE ALSO USED TO TREAT CHRONIC (LONG TERM)
HBV INFECTION IN CHILDREN
AND ADOLESCENTS AGED 2 YEARS TO LESS THAN 18 YEARS.
Entecavir Viatris can be used in children whose
liver is damaged but still functions properly (compensated liver
disease).
Infection by the hepatitis B virus can lead to damage to the liver.
Entecavir Viatris reduces the amount
of virus in your body, and improves the condition of the liver.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ENTECAVIR VIATRIS
_ _
DO NOT TAKE ENTECAVIR VIATRIS

IF YOU ARE ALLERGIC (HYPERSENSITIVE)
to entecavir or any of the other ingredients of this medicine
(listed in section 
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Entecavir Viatris 0.5 mg film-coated tablets
Entecavir Viatris 1 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Entecavir Viatris 0.5 mg film-coated tablets
Each film-coated tablet contains entecavir monohydrate equivalent to
0.5 mg entecavir.
Entecavir Viatris 1 mg film-coated tablets
Each film-coated tablet contains entecavir monohydrate equivalent to 1
mg entecavir.
Excipient with known effect
_Entecavir Viatris 0.5 mg film-coated tablets _
Each film-coated tablet contains 62.5 mg lactose monohydrate.
_ _
_Entecavir Viatris 1 mg film-coated tablets _
Each film-coated tablet contains 125 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Entecavir Viatris 0.5 mg film-coated tablets
White, film-coated, round, biconvex, beveled edge tablet debossed with
“M” on one side and “EA” on
the other side. Diameter: approximately 6.8 mm.
_ _
Entecavir Viatris 1 mg film-coated tablets
_ _
_ _
White, film-coated, round, biconvex, beveled edge tablet debossed with
“M” on one side and “EB” on
the other side. Diameter: approximately 8.8 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Entecavir Viatris is indicated for the treatment of chronic hepatitis
B virus (HBV) infection (see
section 5.1) in adults with:

compensated liver disease and evidence of active viral replication,
persistently elevated
serum alanine aminotransferase (ALT) levels and histological evidence
of active
inflammation and/or fibrosis.

decompensated liver disease (see section 4.4)
For both compensated and decompensated liver disease, this indication
is based on clinical trial data in
nucleoside naive patients with HBeAg positive and HBeAg negative HBV
infection. With respect to
patients with lamivudine-refractory hepatitis B, see sections 4.2, 4.4
and 5.1.
3
Entecavir Viatris is also indicated for the treatment of chronic HBV
infection in nucleoside naive
paediatr
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto bulgaria 16-01-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 26-10-2017
Pakkausseloste Pakkausseloste espanja 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto espanja 16-01-2024
Pakkausseloste Pakkausseloste tšekki 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto tšekki 16-01-2024
Pakkausseloste Pakkausseloste tanska 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto tanska 16-01-2024
Pakkausseloste Pakkausseloste saksa 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto saksa 16-01-2024
Pakkausseloste Pakkausseloste viro 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto viro 16-01-2024
Pakkausseloste Pakkausseloste kreikka 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto kreikka 16-01-2024
Pakkausseloste Pakkausseloste ranska 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto ranska 16-01-2024
Pakkausseloste Pakkausseloste italia 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto italia 16-01-2024
Pakkausseloste Pakkausseloste latvia 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto latvia 16-01-2024
Pakkausseloste Pakkausseloste liettua 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto liettua 16-01-2024
Pakkausseloste Pakkausseloste unkari 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto unkari 16-01-2024
Pakkausseloste Pakkausseloste malta 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto malta 16-01-2024
Pakkausseloste Pakkausseloste hollanti 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto hollanti 16-01-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 26-10-2017
Pakkausseloste Pakkausseloste puola 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto puola 16-01-2024
Pakkausseloste Pakkausseloste portugali 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto portugali 16-01-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 26-10-2017
Pakkausseloste Pakkausseloste romania 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto romania 16-01-2024
Pakkausseloste Pakkausseloste slovakki 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto slovakki 16-01-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 26-10-2017
Pakkausseloste Pakkausseloste sloveeni 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto sloveeni 16-01-2024
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 26-10-2017
Pakkausseloste Pakkausseloste suomi 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto suomi 16-01-2024
Pakkausseloste Pakkausseloste ruotsi 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto ruotsi 16-01-2024
Pakkausseloste Pakkausseloste norja 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto norja 16-01-2024
Pakkausseloste Pakkausseloste islanti 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto islanti 16-01-2024
Pakkausseloste Pakkausseloste kroatia 16-01-2024
Valmisteyhteenveto Valmisteyhteenveto kroatia 16-01-2024

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia